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Background: Current tests for diagnosing liver disease in dogs are sub-optimal. MicroRNA-122
(miR-122) is a sensitive and specific biomarker of liver injury in humans and rodents. Circulating
miR-122 could have utility in identifying dogs with liver disease.
Objective: Establish the reference interval for miR-122 in healthy dogs and determine perfor-
mance in a range of dog breeds with liver disease and control animals with non-liver disease.
Animals: Stored serum from 120 healthy dogs, 100 dogs with non-liver diseases, and 30 dogs
with histologically confirmed liver disease was analyzed.
Methods: Retrospective study. Medical records of dogs with liver disease, non-liver disease and
healthy dogs were reviewed. Serum miR-122 concentrations were measured by PCR and com-
pared with the characteristics of the dogs and their conventional clinical measurements.
Results: In healthy dogs the 2.5th, 50th, and 97.5th quartiles of miR-122 were 110 (90% CI
80-114), 594 (505-682), and 3312 (2925-5144) copies/μL, respectively. There was no differ-
ence between healthy dogs and dogs with non-liver disease (median  IQR: healthy dogs
609 [327-1014] copies/μL; non-liver disease 607 [300-1351] copies/μL). miR-122 was higher in
dogs with liver disease (11 332 [4418-20 520] copies/μL, P < .001 compared to healthy dogs).
miR-122 identified dogs with liver disease with high accuracy (receiver operating characteristic
area under curve for comparison with healthy dogs: 0.93 [95% CI 0.86-0.99]). The upper limit of
normal for healthy dogs (3312 copies/μL) had a sensitivity of 77% and specificity of 97% for
identifying liver disease.
Conclusion and Clinical Importance: Liver disease can be sensitively and specifically diagnosed
in dogs by measurement of miR-122.
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biomarker, canine, hepatic, microRNA
Abbreviations: C, degree celsius; μL, microliter; ALT, alanine aminotransferase activity; ANOVA, analysis of variance; AP, alkaline phosphatase activity; AST, aspartate
aminotransferase activity; AUC, area under the curve; C. elegans, Caenorhabditis elegans; cDNA, complementary deoxyribonucleic acid; CI, confidence intervals; cop-
ies/μL, copies per microliter; Cq, quantification cycle; CV, coefficient of variation; DILI, drug-induced liver injury; EMA, European Medicines Agency; F, female; FDA,
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no enzyme control; ng/μL, nanogram per microliter; NTC, no template control; P, P-value for statistical significance; PCR, Polymerase chain reaction; R(D)SVS, Royal
(Dick)School of Veterinary Studies; RNA, ribonucleic acid; ROC, receiver operator characteristic; RT-PCR, real-time polymerase chain reaction; TE, tris-EDTA; U/L,
units per liter
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1 | INTRODUCTION
Liver disease is a major cause of morbidity and mortality in dogs.1 To
reach a definitive diagnosis clinicians measure a panel of biochemical
blood variables to identify dogs that would benefit from subsequent
imaging and histopathological evaluation of liver biopsy specimens.
The most commonly used circulating biochemical indicators of liver
injury are alanine aminotransferase activity (ALT), aspartate amino-
transferase activity (AST), alkaline phosphatase activity (AP), and
gamma-glutamyltransferase activity (GGT). However, these current
biochemical assays have sub-optimal sensitivity and specificity for
detection of histologically confirmed liver disease.2 Consequently,
only ALT, which is present in high concentrations within the cyto-
plasm and mitochondria of canine hepatocytes, is widely used to
assess dogs for the presence of liver injury and has emerged as the
gold-standard marker of hepatocellular injury. The degree of increased
serum ALT activity is roughly proportional to disease severity, but
ALT might not increase (“false negative”) in a number of different sce-
narios such as reduced hepatocyte number due to advanced fibrosis,
non-inflammatory primary or secondary neoplasia, and early in the
course of hepatocellular disease.3,4 Other non-liver diseases (eg, dia-
betes mellitus and hemolysis) might also result in elevated serum ALT
activity.3,4 In 191 clinically healthy labradors with histopathological
abnormalities in the liver, the sensitivity of ALT and AP was only 45%
(95% CI: 25%-65%) and 15% (0%-35%), respectively, for reporting
acute hepatitis.2 In the setting of chronic hepatitis, sensitivity was
71% (47%-94%) and 13% (0%-31%), respectively, for ALT and AP.2
For most liver diseases, histopathological evaluation of liver
biopsy samples is needed for a definitive diagnosis and is used as the
reference standard against which the accuracy of the other tests is
compared. However, biopsy remains an invasive, costly procedure
with associated risks of complications from the procedure. For exam-
ple, a retrospective study demonstrated that 4% of dogs undergoing
liver biopsy required a post-procedure blood transfusion.5 In sum-
mary, there is a clear and urgent need to develop better diagnostic
tests that will allow clinicians to diagnose liver disease in dogs earlier,
and more accurately target invasive liver biopsy to dogs with a high
likelihood of having serious liver disease.
MicroRNAs (miRNAs) are small (~22 nucleotide-long) non-protein
coding RNAs that regulate post-transcriptional gene expression.6 The
properties of circulating microRNAs that support their utility as bio-
markers include organ specificity (for certain microRNA species), rela-
tive stability in blood and their ability to be amplified and measured
by polymerase chain reaction (PCR). miR-122 is highly expressed in
hepatocytes accounting for up to 70% of the total liver miRNA con-
tent.7 Multiple studies have demonstrated the sensitivity and specific-
ity of miR-122 as a circulating biomarker of liver injury in
chimpanzees,8 mice,9 rats,10 zebrafish,11 and in human studies of dif-
ferent liver diseases including drug-induced liver injury (DILI),12 hepa-
titis C,13 and ethanol consumption.14 miR-122 has received regulatory
support for further qualification by the US Food and Drug Administra-
tion (FDA) and the European Medicines Agency (EMA) in the context
of DILI.15,16 Importantly, miR-122 has enhanced sensitivity and speci-
ficity when compared with standard biomarkers. For example, miR-
122 accurately reports human DILI after acetaminophen overdose at
first presentation to hospital at a time when current markers, such as
ALT, are still within normal ranges.17,18
In dogs there have been a limited number of studies that suggest
circulating miR-122 could have utility in diagnosing liver disease. In a
pre-clinical drug development study, ALT was elevated in the absence
of abnormal liver histology in beagles.19 In this study miR-122 was
measured and had increased specificity with regard to excluding
important histological liver abnormality. In a study of 66 Labrador
retrievers, miR-122 was reported to be a specific and sensitive bio-
marker for liver injury and copper accumulation.20 The same research
group reported that circulating miR-122 is particularly elevated in Lab-
rador retrievers with mucoceles.21 These discovery studies investi-
gated only small numbers of a single breed of dog, namely labradors,
and were insufficiently sized to determine the normal reference inter-
val for miR-122. Also, they did not include unwell dogs with non-liver
pathology (an important control population needed to establish bio-
marker specificity). Building on our biomarker qualification experience
in humans, the aims of this study were to establish the reference
interval for serum miR-122 concentration in healthy dogs and then
determine the sensitivity and specificity of miR-122 as a biomarker of
liver injury across multiple dog breeds.
2 | METHODS
2.1 | Animals
All dogs were recruited to this study at the Royal (Dick) School of Vet-
erinary Studies (R[D]SVS), Edinburgh, UK. Healthy dogs presenting to
the R[D]SVS general practice for routine annual vaccination, who had
a normal history and clinical examination, were invited to have a
serum biochemical health screen which included measurement of
ALT. miR-122 was measured in consecutive healthy dogs which had a
normal serum ALT activity. Consecutive dogs who had a final diagno-
sis of non-primary liver disease, had ALT measured as part of their
clinical evaluation and had a residual serum sample retained were also
enrolled into the study. Finally, consecutive dogs that had a diagnostic
assessment which included histopathological examination of a liver
biopsy and serum ALT measurement leading to definitive diagnosis of
a primary liver disorder were enrolled into the study. The histopatho-
logical diagnosis was classified according to World Small Animal Vet-
erinary Association (WSAVA) criteria by a board certified
pathologist.22 The study was approved by The University of Edin-
burgh Veterinary Ethics Research Committee.
2.2 | RNA isolation
Serum samples were stored at −80C until miRNA analyses. The
median time in storage between blood sampling and RNA isolation
was 402 days (IQR: 207-593, n = 250) with 1091 days being the maxi-
mum storage time. This is less time in storage compared with pub-
lished studies that demonstrate miRNA stability when frozen.23,24
miRNA was extracted using a miRNeasy Serum/Plasma kit (Qiagen,
Venlo, Netherlands) following the manufacturer’s instructions. Total
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RNA was extracted from 50 μL of serum diluted in 150 μL nuclease
free water. Briefly, RNA was extracted from the serum by lysis
reagent (1000 μL) and chloroform (200 μL). After centrifugation at
12 000g for 15 min at 4C up to 600 μL of the aqueous phase was
transferred to a new tube with 900 μL absolute ethanol. RNA was
purified on a RNeasy minElute spin column and eluted in 15 μL
RNase-free water and stored at −80C. Extraction efficiency was
monitored by adding 5.6 × 108 copies of synthetic C. elegans miR-39
spike-in control after the addition of lysis reagent before the addition
of chloroform and phase separation.
2.3 | Reverse transcription and real-time polymerase
chain reaction (RT-PCR)
The miScript II Reverse Transcription kit was used to prepare cDNA
according to the manufacturer’s instructions. Briefly, 2.5 μL of RNA
eluate was reverse transcribed into cDNA. The synthesised cDNA
was diluted and used for cDNA template in combination with the miS-
cript SYBR Green PCR kit (Qiagen, Venlo, The Netherlands) using the
specific miScript assays (Qiagen, Venlo, The Netherlands). RT-PCR
was performed in duplicate on a Light Cycler 480 (Roche, Burgess Hill,
UK) using the recommended miScript cycling parameters.
In the current study, miRNA was quantified as copy number per
μL by generating a standard curve. A calibration curve of Cq as a func-
tion of miRNA was determined by performing PCR on miR-39 at 5 ×
105, 5 × 104, 5 × 103, and 5 × 102 copies/μL (independent from serum
samples) according to manufacturer’s protocol (miRNeasy Serum/
Plasma Spiked-In Control, Qiagen). This calibration curve was used to
determine the recovery of miR-39 from the samples based on the
10 800 copies/μL spiked control in the final PCR reaction. The calibra-
tion curve was also used to determine the concentration of miR-122
in each sample following the protocol reported in the miRNeasy
Serum/Plasma Handbook. Concentrations of miR-122 were corrected
for the recovery measured for miR-39.
Repeatability was determined by measuring the intra-assay vari-
ability of miR-122 duplicates and was deemed acceptable as per pre-
vious studies25 and expressed as concentration (copies/μl) per MIQE
guidelines26 (CV: 11.84% [3.21%-15.92% IQR]). Reproducibility was
determined by measuring inter-assay variability across plates and days
by measuring miR-122 concentrations (copies/μL) of reference sam-
ples. Variability was acceptable (CV 18.25% [7.55%-25.92% IQR]).25 A
no enzyme control (NEC), omitting the reverse transcriptase enzyme
during reverse transcription, and no template control (NTC) omitting
the cDNA in the RT-PCR plate were also included in every run. NEC
and NTC controls had Cq values of 40. Cq values less than 40 were
regarded as positive amplification signals.
2.4 | Sample size
The International Federation of Clinical Chemistry (IFCC) recommends
that samples from 120 or more individuals are required for the devel-
opment of reference intervals for analytes.27
2.5 | Statistical analyses
Data were summarized as median and range for summary statistics of
the study subjects. Serum miR-122 concentrations from healthy dogs
were used to calculate the overall reference intervals following recom-
mended approaches.28,29 The following three R packages were used:
Outliers,30 jmuOutlier,31 and Quantreg.32 Firstly, the distribution of
miR-122 concentrations was investigated using visual inspection of
QQ plots to determine whether it required a log or square root trans-
formation. The appropriate transformation was applied, if required, to
the miR-122 concentrations to approximate a Gaussian distribution,
fulfilling the normality assumption of subsequent analyses. Outliers
were identified and removed according to Tukey’s method.33 The dis-
tribution of the miR-122 concentrations, transformed (if appropriate)
and with outliers removed, was inspected for an approximate Gauss-
ian distribution before references intervals were calculated. The 2.5th
and 97.5th quartiles were derived in order to calculate the 95% refer-
ence intervals for miR-122 concentration. The 90% confidence inter-
vals (CI) for the reference intervals were calculated through non-
parametric methods.34
Differences in miR-122 concentrations and different breeds were
calculated by non-parametric, Kruskal–Wallis test by ranks. The differ-
ence in miR-122 concentration between female and male dogs was
measured by non-parametric Mann–Whitney U test. Associations
between age and body weight and miR-122 concentrations were cal-
culated by Spearman’s rank correlations and simple linear regression.
Differences between miR-122 concentrations in healthy controls,
non-liver disease and liver disease subjects were measured by non-
parametric Kruskal–Wallis test by ranks. Associations between ALT
and miR-122 in healthy controls, non-liver disease and liver disease
subjects were measured by Spearmans’ rank correlations and simple
linear regression. Receiver operating characteristic (ROC) curve ana-
lyses were used to determine the sensitivity and specificity of miR-
122 and ALT for detecting the presence of liver disease in dogs. Dif-
ferences between the area under the curve (AUC) between miR-122
and ALT ROC curves were measured as per Hanley and McNeils
method.35 Normally distributed data were presented as mean  stan-
dard deviation and non-normally distributed data as median and inter-
quartile range. Nominal P values equal to or less than.05 were consid-
ered significant. Statistical analyses were performed using Graphpad
Prism (GraphPad Software, La Jolla, California).
3 | RESULTS
3.1 | Dog characteristics
Serum samples from 250 dogs were analyzed (120 healthy, 100 with
non-liver diseases, and 30 with histologically confirmed liver disease).
Characteristics of the healthy dogs including sex, age, breed, and clini-
cal chemistry results are summarized in Table 1. The diagnoses of the
dogs with non-liver disease are listed in Supporting Information
TableS1. All the dogs with non-liver disease had normal range serum
ALT activity (median: 42 U/L. IQR: 29-53). The characteristics of the
dogs with liver disease are presented in Table 2.
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3.2 | Reference intervals of miR-122 in healthy dogs
Firstly, we investigated whether breed, sex, age, and weight in healthy
dogs influenced circulating miR-122 concentrations. There were no
significant differences in miR-122 concentration across the different
breeds (breeds with more than three dogs per group are presented in
Figure 1A). Similarly, there was no difference between female and
male dogs in this healthy cohort (Figure 1B). No significant relation-
ship was found between circulating miR-122 concentration and dog
body weight or age (Figure 1C,D).
TABLE 1 Characteristics of the healthy dog group (n = 120 per group)
Breed (n = 120) Sex (F, M) Age (years) Weight (kg) ALT (U/L) miR-122 (copies/μL)
Labrador Retriever and cross breed (n = 31) F20, M11 5 (3.5-9) 27.6 (25.1-31.4) 36 (31.5-44.5) 486.1 (299.5-821.7)
Collie Border and cross breed (n = 11) F7, M4 9 (6.5-10.5) 22.5 (20.5-24.7) 40 (32.5-45) 599.2 (496.3 - 2434.1)
Cocker Spaniel (n = 11) F7, M4 4 (3-10) 15.4 (13.5-17.8) 30 (28-42) 774.7 (247.7 - 957.2)
Labrador Poodle (n = 6) F2, M6 5.5 (3.5-6.8) 19.9 (13.7-22.8) 30 (27.5-4.8) 487.9 (271.3-799.2)
Golden retriever (n = 6) F2, M4 2.5 (2-5.25) 29.4 (25.5-31.3) 35 (33-46) 675.8 (644.8-812.1)
Border terrier (n = 5) F2, M3 8 (7-8) 10.5 (8.5-12.1) 34 (25-51) 769.8 (741.1-852)
Staffordshire bull terrier (n = 4) F4 9 (7-10.3) 20.1 (18.3-22.7) 33 (29-38) 561.7 (489.9-743.7)
English Springer Spaniel (n = 4) F2, M2 9 (6.5-10.5) 19.6 (18.3-21.4) 28 (26-31) 320.4 (104.6-1213.1)
Jack Russel terrier (n = 4) F3, M1 5.5 (4.3-6.5) 7 (6.8-7.4) 36 (26.8-52.5) 1314.7 (451.2-2168.6)
Lurcher (n = 3) M3 5 (5-6.5) 25.7 (20.1-29.7) 44 (42-47.5) 467.9 (454.9-576.2)
Whippet (n = 3) F1, M2 4 (3.5-4) 17.2 (15.1-18.55) 20 (19-31) 508.11 (494.8-1827.4)
Cross breed terrier (n = 2) F2 8.5 (8.2-8.8) 10.6 (9.7-11.5) 32.5 (29.2-35.8) 584.7 (341.8-827.7)
Cross breed (n = 3) F2, M1 4 (3-4.5) 22.9 (22-25) 39 (32-52) 812.4 (579.3-1574)
French bulldog (n = 2) F2 6 (3.5-8.5) 12.4 (12-12.8) 42.5 (38.8-46.2) 1002.6 (556.6-1448.6)
Shih tzu (n = 2) F1, M1 10.5 (10.2-10.8) 9.55 (7.9-11.18) 47 (46-48) 601.44 (497.2-705.7)
West Highland terrier (n = 2) F1, M1 6 (5.5-6.5) 9.9 (9.63-10.23) 48 (35.5-60.5) 1335.8 (1163.9 - 1507.6)
Beagle F1 3 17.7 22 180.7
Boxer M1 4 26 39 182.4
Chinese crested F1 10 8.3 47 988.9
Dachshund M1 6 13.8 30 537.9
Doberman F1 7 30 35 247.4
Dogue de Bordeaux M1 4 33.4 75 2110.3
English Mastiff M1 5 81 71 4446.1
English Pointer F1 5 23.7 52 1067.2
German Shepherd F1 3 28.6 37 426.8
Greyhound F1 2 26.3 53 114.5
Hungarian Viszla F1 9 21.5 45 642.5
Ihasa Apso M1 2 9.6 682.4
Miniature Schnauzer M1 8 9 42 140.5
Newfoundland M1 6 70.8 17 1020.8
Pomeranian M1 5 3.2 84 1755.7
Poodle M1 2 6.4 31 543.1
Rhodesian Ridgeback F1 11 47.3 49 371.2
Rottweiler F1 3 40.3 21 230.7
SBT Cross F1 8 24.9 59 871.4
Tibetan Mastiff M1 1 40.4 38 636.4
Utonagan F1 2 33 47 1766.9
Continuous variables are expressed as median and inter-quartile range. F, female; M, male; kg, kilogram; U/L, units per liter.
TABLE 2 Characteristics of the dogs with histologically confirmed liver disease
Liver disease (n = 30) Sex (F, M) Age (years) Weight (kg) ALT (U/L) miR-122 (copies/μL)
Fibrosis (n = 6) F2, M4 6 (3.5-8.3) 24.8 (18.9-27.8) 452 (244-564) 13 466 (6752-22 142)
Inflammatory (n = 19) F12, M7 7 (6-8) 25 (10.8-29.8) 207 (169-406) 11 696 (4902-20 086)
Neoplastic (n = 5) F3, M2 11 (9-11) 10.9 (10.1-15.5) 194 (182-233) 9065 (3001-11 188)
Continuous variables are expressed as median and inter-quartile range. F, female; M, male; kg, kilogram; U/L, units per liter.
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Secondly, we determined the reference interval for circulating
miR-122 in healthy dogs (n = 120, as per IFCC guidelines). The data
were normalized by a log transformation. After transformation, two
values were removed as outliers (values: 8121 and 6651 copies/μL).
The distribution of miR-122 in healthy dogs is presented in Supporting
Information Figure S1. The 2.5th, 50th, and 97.5th quartile of miR-
122 were 110 (80-114), 594 (505-682), and 3312 (2925-5144) cop-
ies/μL, respectively. The 97.5th quartile represents the upper limit of
normal (ULN) for this reference population.
3.3 | miR-122 serum concentrations in dogs with
disease
Circulating miR-122 was measured in the three groups of dogs
(Figure 2). There was no difference between healthy dogs and dogs
with non-liver disease (median  IQR: healthy dogs 609 [327-1014]
copies/μL; non-liver disease 607 [300-1351] copies/μL). By contrast,
miR-122 concentration was substantially higher in dogs with liver dis-
ease (11 332 [4418-20 520] copies/μL). The histopathological findings
in the liver were grouped into fibrosis, inflammatory, and neoplastic
processes. miR-122 was significantly elevated in all these sub-groups
compare with healthy dogs but did not differ across processes
(Figure 3A). In those dogs with liver disease, miR-122 concentration
had a significant correlation with ALT activity (Figure 3B).
We performed ROC analysis to quantify the performance of miR-
122 with regard to separation of liver disease from the other two
groups (Supporting Information Figure S2). miR-122 identified dogs
with liver disease with high accuracy (ROC area under curve [AUC]
for comparison with healthy dogs: 0.93 [95% CI 0.86-0.99]). The ULN
for healthy dogs (3312 copies/μL) had a sensitivity of 77% (95% CI:
58%-90%) and specificity of 97% (95% CI: 93%-99%) for identifying
liver disease compared to healthy dogs (positive likelihood ratio 30).
miR-122 similarly identified dogs with liver disease with high accuracy
in comparison with non-liver disease dogs: ROC-AUC for comparison
with non-liver disease: 0.91 (95% CI 0.84-0.98). When liver disease
dogs were compared to dogs with non-liver disease the ULN for
healthy dogs had a sensitivity and specificity of 77% (95% CI: 58%-
90%) and 88% (95% CI: 80%-94%), respectively (positive likelihood
ratio 7). The accuracy of miR-122 was similar to ALT (ROC-AUC for
comparison of liver disease with healthy dogs: 0.96 (95% CI: 0.92-1).
P = .09 when compared with miR-122 ROC-AUC (liver disease dogs
compared to healthy dogs) by Hanley and McNeil test. ROC-AUC for
the ALT comparison with non-liver disease dogs: 0.95 (95% CI:
0.90-1). P = .06 when compared with miR-122 ROC-AUC by Hanley
and McNeil test).
FIGURE 1 Relationship between characteristics and circulating miR-
122 concentration in healthy dogs (n = 120). (A) No significant
differences between different breeds in circulating miR-122. Groups
with more than 3 dogs are included and presented. Labrador (n = 31),
Cocker spaniel (n = 11), Collie (n = 11), Labrador poodle (n = 6),
Golden retriever (n = 6), Border terrier (n = 5), Staffordshire terrier
(n = 4), Springer spaniel (n = 4), Jack Russel terrier (n = 4), Lurcher (n =
3), and Whippet (n = 3) included in one-way Kruskal–Wallis ANOVA
(P = .68). (B) No significant differences between female (n = 71) and
male (n = 49) dogs in circulating miR-122. Data are presented as a
Tukey plot (P = .54 by Mann–Whitney test). C. Correlation and linear
regression of circulating miR-122 and age demonstrated no significant
relationship (P = .27, R = 0.10, n = 120). D. Correlation and linear
regression of miR-122 and body weight demonstrated no significant
relationship (P = .14, Spearman r = −0.19, n = 120)
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4 | DISCUSSION
This study defines the normal reference interval for circulating miR-
122 concentration in healthy dogs and demonstrates the sensitivity
and specificity of circulating miR-122 concentration as a biomarker of
liver disease across multiple dog breeds. Importantly, this study
included dogs with non-liver disease and established the specificity of
miR-122 for liver pathology.
Current biochemical blood variables used as markers of liver dis-
ease in dogs have significant limitations and the gold standard to
reach a definitive diagnosis remains histopathological evaluation of
liver biopsy samples. It would, therefore, be of great value to develop
a non-invasive liver disease biomarker that can reliably detect liver
disease with high specificity and sensitivity across different dog
breeds. MicroRNAs are emerging as biomarkers for several diseases
due to their organ specificity, ease of measurement, potential for
amplification, and relative stability in the blood. Several multicenter
studies have demonstrated the utility of circulating miR-122 as a bio-
marker of liver disease in humans and this has led to circulating miR-
122 receiving FDA support as a biomarker of DILI. However, data in
the veterinary field and especially across different dog breeds remain
scarce.
In the present study, we were the first to establish a normal refer-
ence interval of circulating miR-122 concentrations in healthy dogs
across several different dog breeds. Interestingly, this reference inter-
val is comparable to the normal reference interval in humans,36 which
might reflect this microRNA’s concentration in the circulation being
under tight regulation. However, the mechanism of miR-122 release
into, and clearance from, the circulation in healthy animals remains
undefined. We were also able to demonstrate that there were no sig-
nificant differences in miR-122 concentrations across different age-,
sex-, and dog breed groups, which in turn further enhances the cur-
rent literature available on circulating miR-122 concentrations in dogs.
These findings build on previous studies which have reported no dif-
ferences in miR-122 concentration between female and male dogs
and no age-related differences.20 Previously, the available literature
on microRNA concentrations in dogs could only postulate on the con-
sistency in miR-122 concentrations between different dog breeds
based on the highly conserved nature of miRNA between species with
similar physiology,20 a hypothesis which we were able to support in
this study. In our study dogs were classified as healthy based on clini-
cal history, examination, and routine clinical chemistry. A challenge for
all biomarker studies is to have confidence that the healthy population
are truly healthy and do not have members with sub-clinical disease
which may be reported by the new biomarker in development (ie, a
false positive result in a healthy population is actually a true positive
which has been incorrectly classified due to limitations of the gold
standard test). In the absence of histological analysis of liver tissue
from healthy dogs at the time of blood sampling a strategy for future
work is to longitudinally follow dogs for disease development and
relate this to miR-122 at baseline.
Secondly, circulating miR-122 was able to discriminate between
dogs with liver disease and both healthy dogs and dogs with non-liver
(A)
(B)
FIGURE 3 miR-122 concentration in liver disease. (A) Increased miR-
122 concentration in fibrotic (n = 6), inflammatory (n = 19) and
neoplastic (n = 5) etiologies of liver disease compared to healthy dogs
(n = 120) as determined by one-way Kruskal–Wallis ANOVA (P = .02
healthy vs fibrotic, P = .0006 healthy vs inflammatory and P = .05
healthy vs neoplastic, respectively). There was no difference in miR-
122 concentration across the liver pathology groups (P = .92 fibrotic
vs inflammatory, P = .30 fibrotic vs neoplastic and P = .27
inflammatory vs neoplastic group) as determined by one-way
Kruskal–Wallis ANOVA. Data are presented as Tukey plots. (B) There
was a significant relationship between mir-122 concentration and ALT
as determined by correlation and linear regression (P = .005,
Spearman r = .49, n = 30)
FIGURE 2 Circulating miR-122 concentration in healthy dogs (n =
120) and in dogs with non-liver diseases (n = 100) and liver disease
(n = 30). Data are presented as Tukey plots. The significance of
differences between the groups were determined by one-way
Kruskal–Wallis ANOVA
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disease with a significantly higher miR-122 concentration in the liver
disease dog cohort. The sensitivity and specificity of miR-122 was com-
parable to our human studies of patients with acetaminophen toxicity
but the dogs with liver disease in this study were heterogeneous with
regard to the underlying disease etiology. This supports miR-122 having
a potential context of use as a screening tool for liver disease in dogs.
The results from this study are a promising step in further develop-
ing circulating miR-122 as a qualified biomarker of liver disease in dogs.
It remains to be conclusively determined as to whether miR-122 can
accurately detect liver disease when current markers such as ALT are
still in their respective reference interval (a specific context of use for
miR-122 in humans). In the present study we could not test this as the
diagnosis of liver disease was already made using ALT to indicate need
for liver biopsy. Future studies with prospective, serial, blood sampling
are needed to determine the clinical utility of miR-122 in dogs. How-
ever, published work in Labradors supports miR-122 reporting liver dis-
ease when ALT is still in its normal reference interval.20 Furthermore, as
microRNA biomarkers are translatable across species, we believe it is
justifiable to cautiously extrapolate human and rodent data to veteri-
nary practice. In humans16 and mice9, it is conclusively demonstrated
that miR-122 is more sensitive than ALT, at least in the context of DILI.
We would predict the same performance in dogs and the present study
would suggest utility across a range of liver diseases. An important hur-
dle to overcome is developing a point-of-care assay that clinicians could
use to measure miR-122 in a timely and cost-efficient manner. The
“market pull” from both human medicine and drug development has
resulted in promising assays that could be applied to veterinary medi-
cine because of the sequence conservation of miR-122.37
In summary, miR-122 is a sensitive and specific biomarker for liver
disease in dogs. With further development it could become a valuable
tool in the diagnostic evaluation and treatment pathway of dogs with
suspected liver disease.
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